Pharmacy

Your Article Summary

See Latest Articles

Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint
Genzyme, 05/21/09

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) met its primary endpoint, with a 25 percent reduction in LDL cholesterol after 26 weeks of treatment, vs. 3 percent for placebo. This study also met each of its three secondary endpoints of reduction in apolipoprotein B, total cholesterol and non-HDL cholesterol.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09

Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials
The Lancet - Early Online Publication, 12/01/09

Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09

 See all of Drug Trials

Today in Major Studies...keeping you current

Receive free subspecialty "5-minute updates" via email

In vitro Growth Inhibitory Activity and Malaria Risk in a Cohort Study in Mali
Infection and Immunity, 12/01/09

A Multicenter, Double-Blind, Randomized, Parallel Group Study Comparing Polyvinyl Chloride and Polyvinyl Chloride-Free Catheter Materials
The Journal of Urology, 11/24/09

Carboplatin-Pemetrexed Adjuvant Chemotherapy in Resected Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Anticancer Research, 11/16/09

 See all of Major Studies